References
Phosphate Salts
1
Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
15
McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
275
Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.
505
Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
2208
Breslau NA, Heller HJ, Reza-Albarran AA, Pak CY. Physiological effects of slow release potassium phosphate for absorptive hypercalciuria: a randomized double-blind trial. J Urol 1998;160:664-8. View abstract.
2209
Heller HJ, Reza-Albarran AA, Breslau NA, Pak CY. Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria. J Urol 1998;159:1451-5; discussion 1455-6. View abstract.
2494
Hill AG, Teo W, Still A, et al. Cellular potassium depletion predisposes to hypokalaemia after oral sodium phosphate. Aust N Z J Surg 1998;68:856-8. View abstract.
2495
Clarkston WK, Tsen TN, Dies DF, et al. Oral sodium phosphate versus sulfate-free polyethylene glycol electrolyte lavage solution in outpatient preparation for colonoscopy: a prospective comparison. Gastrointest Endosc 1996;43:42-8. View abstract.
2496
Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997;29:103-5. View abstract.
2497
DiPalma JA, Buckley SE, Warner BA, et al. Biochemical effects of oral sodium phosphate. Dig Dis Sci 1996;41:749-53. View abstract.
2498
Helikson MA, Parham WA, Tobias JD. Hypocalcemia and hyperphosphatemia after phosphate enema use in a child. J Pediatr Surg 1997;32:1244-6. View abstract.
2499
Galloway SD, Tremblay MS, Sexsmith JR, Roberts CJ. The effects of acute phosphate supplementation in subjects of different aerobic fitness levels. Eur J Appl Physiol Occup Physiol 1996;72:224-30. View abstract.
2677
Shils ME, Olson JA, Shike M, Ross AC, eds. Modern Nutrition in Health and Disease. 9th ed. Baltimore, MD: Williams & Wilkins, 1999.
3092
Fauci AS, Braunwald E, Isselbacher KJ, et al. Harrison's Principles of Internal Medicine, 14th ed. New York, NY: McGraw-Hill, 1998.
3094
Yates AA, Schlicker SA, Suitor CW. Dietary reference intakes: The new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699-706. View abstract.
3371
Harmelin DL, Martin FR, Wark JD. Antacid-induced phosphate depletion syndrome presenting as nephrolithiasis. Aust NZ J Med 1990;20:803-5. View abstract.
3372
Roberts DH, Knox FG. Renal phosphate handling and calcium nephrolithiasis: role of dietary phosphate and phosphate leak. Semin Nephrol 1990;10:24-30. View abstract.
4400
Spencer H, Menaham L. Adverse effects of aluminum-containing antacids on mineral metabolism. Gastroenterology 1979;76:603-6. View abstract.
4455
West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975;16:93-8. View abstract.
4460
Schwarz KB, Goldstein PD, Witztum JL, et al. Fat-soluble vitamin concentrations in hypercholestrolemic children treated with colestipol. Pediatrics 1980;65:243-50. View abstract.
4495
Becker GL. The case against mineral oil. Am J Digestive Dis 1952;19:344-8. View abstract.
5838
Heaton KW, Lever JV, Barnard RE. Osteomalacia associated with cholestyramine therapy for post-ileectomy diarrhea. Gastroenterology 1972;62:642-6. View abstract.
6470
Alvarez-Arroyo MV, Traba ML, Rapado TA, et al. Correlation between 1.25 dihydroxyvitamin D serum levels and fractional rate of intestinal calcium absorption in hypercalciuric nephrolithiasis. Role of phosphate. Urol Res 1992;20:96-7. View abstract.
6479
Carey CF, Lee HH, Woeltje KF (eds). Washington Manual of Medical Therapeutics. 29th ed. New York, NY: Lippincott-Raven, 1998.
7555
Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press, 1999. Available at: http://books.nap.edu/books/0309063507/html/index.html.
8301
Duffy DJ, Conlee RK. Effects of phosphate loading on leg power and high intensity treadmill exercise. Med Sci Sports Exerc 1986;18:674-7. View abstract.
8302
Perreault MM, Ostrop NJ, Tierney MG. Efficacy and safety of intravenous phosphate replacement in critically ill patients. Ann Pharmacother 1997;31:683-8. View abstract.
8303
Rosen GH, Boullata JI, O'Rangers EA, et al. Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia. Crit Care Med 1995;23:1204-10. View abstract.
8821
Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr 2002;21:239-44.. View abstract.
8878
Insogna KL, Bordley DR, Caro JF, Lockwood DH. Osteomalacia and weakness from excessive antacid ingestion. JAMA 1980;244:2544-6. View abstract.
9300
Gregory JF. Case study: folate bioavailability. J Nutr 2001;131:1376S-1382S. View abstract.
11503
Saadeh G, Bauer T, Licata A, Sheeler L. Antacid-induced osteomalacia. Cleve Clin J Med 1987;54:214-6. View abstract.
14587
Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. New Engl J Med 1989;320:1110-3. View abstract.
14588
Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf 2003;26:1093-115. View abstract.
14589
Campisi P, Badhwar V, Morin S, Trudel JL. Postoperative hypocalcemic tetany caused by Fleet Phospho-Soda preparation in a patient taking alendronate sodium. Dis Colon Rectum 1999;42:1499-501. View abstract.
14590
Lindsay R, Nieves J, Henneman E, et al. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993;77:1535-9. View abstract.
14591
Monsen ER, Cook JD. Food iron absorption in human subjects IV. The effects of calcium and phosphate salts on the absorption of nonheme iron. Am J Clin Nutr 1976;29:1142-8. View abstract.
14592
Peters T, Apt L, Ross JF. Effect of phosphates upon iron absorption studied in normal human subjects and in an experimental model using dialysis. Gastroenterology 1971;61:315-22. View abstract.
14593
Hergesell O, Ritz E. Phosphate binders on iron basis: a new perspective? Kidney Intl Suppl 1999;73:S42-5. View abstract.
14594
Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis 1989;13:194-9. View abstract.
14595
Leung AC, Henderson IS, Halls DJ, Dobbie JW. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed) 1983;286:1379-81. View abstract.
14596
Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 1996;276:631-6. View abstract.
14597
Lindsay R, Nieves J, Formica C, et al. Randomized controlled study of the effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5. View abstract.
14598
Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone (1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003;88:4214-20. View abstract.
14599
Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 1998;280:1067-73. View abstract.
88107
FDA OTC ingredients list, April 2010. Available at: www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM135691.pdf (accessed 2/7/15).
88133
OsmoPrep Prescribing information. Salix Pharmaceuticals, Raleigh, NC. October 2012. (http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021892s006lbl.pdf, accessed 02/24/15).
88135
Bugg, NC and Jones, JA. Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit. Anaesthesia 1998;53(9):895-902. View abstract.
88144
Elliott, GT and McKenzie, MW. Treatment of hypercalcemia. Drug Intell Clin Pharm 1983;17(1):12-22. View abstract.
88145
Schaiff, RA, Hall, TG, and Bar, RS. Medical treatment of hypercalcemia. Clin Pharm 1989;8(2):108-21. View abstract.
88146
Hu, S, Shearer, GC, Steffes, MW, Harris, WS, and Bostom, AG. Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia. Am J Kidney Dis 2011;57(1):181-2. View abstract.
88147
Savica, V, Calo, LA, Monardo, P, et al. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia. J Ren Nutr 2009;19(1):69-72. View abstract.
88148
Terlevich A, Hearing SD, Woltersdorf WW, et al. Refeeding syndrome: effective and safe treatment with Phosphates Polyfusor. Aliment Pharmacol Ther 2003;17(10):1325-9. View abstract.
88149
Fisher, JN and Kitabchi, AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 1983;57(1):177-80. View abstract.
88150
Folland, JP, Stern, R, and Brickley, G. Sodium phosphate loading improves laboratory cycling time-trial performance in trained cyclists. J Sci Med Sport 2008;11(5):464-8. View abstract.
93837
Brewer CP, Dawson B, Wallman KE, Guelfi KJ. Effect of sodium phosphate supplementation on repeated high-intensity cycling efforts. J Sports Sci. 2015;33(11):1109-16. View abstract.
93843
Buck C, Guelfi K, Dawson B, McNaughton L, Wallman K. Effects of sodium phosphate and caffeine loading on repeated-sprint ability. J Sports Sci. 2015;33(19):1971-9. View abstract.
93844
Buck CL, Henry T, Guelfi K, Dawson B, McNaughton LR, Wallman K. Effects of sodium phosphate and beetroot juice supplementation on repeated-sprint ability in females. Eur J Appl Physiol. 2015 Oct;115(10):2205-13. View abstract.
93846
Ell C, Fischbach W, Layer P, Halphen M. Randomized, controlled trial of 2 L polyethylene glycol plus ascorbate components versus sodium phosphate for bowel cleansing prior to colonoscopy for cancer screening. Curr Med Res Opin. 2014 Dec;30(12):2493-503. View abstract.
93847
Heaney RP, Recker RR, Watson P, Lappe JM. Phosphate and carbonate salts of calcium support robust bone building in osteoporosis. Am J Clin Nutr. 2010 Jul;92(1):101-5. View abstract.
93848
Jung YS, Lee CK, Kim HJ, Eun CS, Han DS, Park DI. Randomized controlled trial of sodium phosphate tablets vs polyethylene glycol solution for colonoscopy bowel cleansing. World J Gastroenterol. 2014 Nov 14;20(42):15845-51. View abstract.
93849
Kopec BJ, Dawson BT, Buck C, Wallman KE. Effects of sodium phosphate and caffeine ingestion on repeated-sprint ability in male athletes. J Sci Med Sport. 2016 Mar;19(3):272-6. View abstract.
93850
Lee SH, Lee DJ, Kim KM, Seo SW, Kang JK, Lee EH, Lee DR. Comparison of the efficacy and safety of sodium phosphate tablets and polyethylene glycol solution for bowel cleansing in healthy Korean adults. Yonsei Med J. 2014 Nov;55(6):1542-55. View abstract.
93851
Manukyan MN, Tolan K, Severge U, Attaallah W, Kebudi A, Cingi A. Prospective randomized comparison of oral sodium phosphate and sennoside A+B calcium lavage for colonoscopy preparation. Surg Laparosc Endosc Percutan Tech. 2011 Apr;21(2):90-3. View abstract.
93853
van Vugt van Pinxteren MW, van Kouwen MC, van Oijen MG, van Achterberg T, Nagengast FM. A prospective study of bowel preparation for colonoscopy with polyethylene glycol-electrolyte solution versus sodium phosphate in Lynch syndrome: a randomized trial. Fam Cancer. 2012 Sep;11(3):337-41. View abstract.
93854
West JS, Ayton T, Wallman KE, Guelfi KJ. The effect of 6 days of sodium phosphate supplementation on appetite, energy intake, and aerobic capacity in trained men and women. Int J Sport Nutr Exerc Metab. 2012 Dec;22(6):422-9. View abstract.
93855
Brewer CP, Dawson B, Wallman KE, Guelfi KJ. Effect of Sodium Phosphate Supplementation on Cycling Time Trial Performance and VO2 1 and 8 Days Post Loading. J Sports Sci Med. 2014 Sep 1;13(3):529-34. View abstract.
93856
Buck CL, Dawson B, Guelfi KJ, McNaughton L, Wallman KE. Sodium phosphate supplementation and time trial performance in female cyclists. J Sports Sci Med. 2014 Sep 1;13(3):469-75. View abstract.
93857
Buck CL, Wallman KE, Dawson B, Guelfi KJ. Sodium phosphate as an ergogenic aid. Sports Med. 2013 Jun;43(6):425-35. View abstract.
93858
Brewer CP, Dawson B, Wallman KE, Guelfi KJ. Effect of repeated sodium phosphate loading on cycling time-trial performance and VO2peak. Int J Sport Nutr Exerc Metab. 2013 Apr;23(2):187-94. View abstract.
93859
Czuba M, Zajac A, Poprzecki S, Cholewa J, Woska S. Effects of Sodium Phosphate Loading on Aerobic Power and Capacity in off Road Cyclists. J Sports Sci Med. 2009 Dec 1;8(4):591-9. View abstract.
93860
Belsey J, Crosta C, Epstein O, Fischbach W, Layer P, Parente F, Halphen M. Meta-analysis: efficacy of small bowel preparation for small bowel video capsule endoscopy. Curr Med Res Opin. 2012 Dec;28(12):1883-90. View abstract.
93861
Belsey J, Crosta C, Epstein O, Fischbach W, Layer P, Parente F, Halphen M. Meta-analysis: the relative efficacy of oral bowel preparations for colonoscopy 1985-2010. Aliment Pharmacol Ther. 2012 Jan;35(2):222-37. View abstract.
93862
Juluri R, Eckert G, Imperiale TF. Polyethylene glycol vs. sodium phosphate for bowel preparation: a treatment arm meta-analysis of randomized controlled trials. BMC Gastroenterol. 2011 Apr 14;11:38. View abstract.
93863
Choi NK, Lee J, Chang Y, Kim YJ, Kim JY, Song HJ, Shin JY, Jung SY, Choi Y, Lee JH, Park BJ. Acute renal failure following oral sodium phosphate bowel preparation: a nationwide case-crossover study. Endoscopy. 2014 Jun;46(6):465-70. View abstract.
93864
Brunelli SM. Association between oral sodium phosphate bowel preparations and kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 Mar;53(3):448-56. View abstract.
93865
Schaefer M, Littrell E, Khan A, Patterson ME. Estimated GFR Decline Following Sodium Phosphate Enemas Versus Polyethylene Glycol for Screening Colonoscopy: A Retrospective Cohort Study. Am J Kidney Dis. 2016 Apr;67(4):609-16. View abstract.
93866
Ladenhauf HN, Stundner O, Spreitzhofer F, Deluggi S. Severe hyperphosphatemia after administration of sodium-phosphate containing laxatives in children: case series and systematic review of literature. Pediatr Surg Int. 2012 Aug;28(8):805-14. View abstract.
93867
Ori Y, Rozen-Zvi B, Chagnac A, Herman M, Zingerman B, Atar E, Gafter U, Korzets A. Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience. Arch Intern Med. 2012 Feb 13;172(3):263-5. View abstract.
93868
Nam SY, Choi IJ, Park KW, Ryu KH, Kim BC, Sohn DK, Nam BH, Kim CG. Risk of hemorrhagic gastropathy associated with colonoscopy bowel preparation using oral sodium phosphate solution. Endoscopy. 2010 Feb;42(2):109-13. View abstract.
94672
Johnson DA, Barkun AN, Cohen LB, et al.; US Multi-Society Task Force on Colorectal Cancer. Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2014;109(10):1528-45. View abstract.
94673
Delegge M, Kaplan R. Efficacy of bowel preparation with the use of a prepackaged, low fibre diet with a low sodium, magnesium citrate cathartic vs. a clear liquiddiet with a standard sodium phosphate cathartic. Aliment Pharmacol Ther. 2005 Jun 15;21(12):1491-5. View abstract.
94674
Visicol Tablets Prescribing information. Salix Pharmaceuticals, Raleigh, NC. March 2013. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021097s016lbl.pdf). Accessed 09/28/17.
104470
Prescribing information: BALVERSA (erdafitinib) tablets. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf. [Accessed: February 26, 2021.]
104471
FDA Drug Safety Communication: FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation. FDA Drug Safety and Availability. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-possible-harm-exceeding-recommended-dose-over-counter-sodium. [Accessed: February 26, 2021.]
104472
Dang JT, Moolla M, Dang TT, et al. Sodium phosphate is superior to polyethylene glycol in constipated patients undergoing colonoscopy: a systematic review and meta-analysis. Surg Endosc. 2020. View abstract.
107007
Ploszczyca K, Gajda R, Czuba M. The effects of sodium phosphate supplementation on the cardiorespiratory system and gross efficiency during exercise under hypoxia in male cyclists: A randomized, placebo-controlled, cross-over study. Nutrients 2021;13(10):3556. View abstract.
107008
Hung SY, Chen HC, Ke TW, et al. Noninferiority clinical trial comparing the bowel cleansing efficacy of sodium phosphate tablets (Quiklean(®)) with a polyethylene glycol/bisacodyl kit. World J Gastroenterol 2021;27(5):428-441. View abstract.
107009
Rastogi A, Bhatt N, Rossetti S, Beto J. Management of hyperphosphatemia in end-stage renal disease: A New Paradigm. J Ren Nutr. 2021;31(1):21-34. View abstract.